Alder Lab
Research Themes
New Publications
Zhao, T., Alder, N.N., Starkweather, A.R., Chen, M.H., Matson, A.P., Xu, W., Balsbaugh, J.L., and Cong, X. (2022) Associations of mitochondrial function, stress, and neurodevelopmental outcomes in early life: a systematic review. Developmental Neuroscience 44: 438-454
Mitchell, W., Tamucci, J.D., Ng, E.L., Liu, S., Birk, A.V., Szeto, H.H., May, E.R., Alexandrescu, A.T., and Alder, N.N. (2022) Structure-activity relationships of mitochondria-targeted pharmacological compounds. Elife 11:e75531
Iovine, J.C., Claypool, S.M., and Alder, N.N. (2021) Mitochondrial compartmentalization: emerging themes in structure and function. Trends in Biochemical Sciences 46: 902-917
Zhang, H., Alder, N.N., Wang, W., Szeto, H., Marcinek, D.J., and Rabinovitch, P.S. (2020) Reduction of elevated proton leak rejuvenates mitochondria in the aged cardiomyocyte. Elife 9:e60827
Mitchell, W., Ng, E.A., Tamucci, J.D., Boyd, K.J., Sathappa, M., Coscia, A., Pan, M., Han, X., Eddy, H.A., May, E.R., Szeto, H.H., and Alder, N.N. (2020) The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry 295: 7452
Alder Lab News
- New Grant from the NIAThe Alder Research Group has received an R01 grant the National Institute of Aging (R01AG065879, “First-in-class Peptide Therapeutics for Mitochondrial Disorders: Molecular Mechanism of Action and Optimization of Design”). This is a five-year grant in the amount of $2.5M to support the development and analysis of therapeutic compounds for aging-related mitochondrial disorders.
- New Grant from the Barth Syndrome FoundationWe have received a $50K grant from the Barth Syndrome Foundation, “Development of Mitochondria-Targeted Peptide Compounds as Barth Syndrome Therapeutics. This work will explore a library of compound variants optimized as therapeutics for treating dysfunctional lipid biogenesis of Barth Syndrome patients.
- New Grant from NIGMSThe Alder Group has received an R01 grant from NIH General Medical Sciences (R01GM136975 , “Mitochondrial Membrane Compartmentalization”) for $774K over two years. This is a multi-PI grant with the group of Dr. Steven Claypool from the Johns Hopkins University School of Medicine.
- New PhD GraduatePhD candidate Melissa Brundin has completed her dissertation “Investigation of the Protein-Membrane Interactions of the Tim23 Channel Subunit” and did a remarkable job at her defense. Congratulations, soon-to-be Dr. Brundin!
Thrilled about our collaborative study now in eLife! New fundamental insights into what makes these promising compounds work #mitochondrialmedicine Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds
Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds
Sequence-variant analogs of mitochondria-targeted tetrapeptides have distinct patterns of membrane-bound conformations, effects ...
doi.org
Excited to share our latest work as a bioRxiv preprint, "Structure-Activity Relationships in the Design of Mitochondria-Targeted Peptide Therapeutics". Many thanks to an outstanding research team!
Structure-Activity Relationships in the Design of Mitochondria-Targeted Peptide Therapeutics
Mitochondria play a central role in metabolic homeostasis; hence, dysfunction of this organelle underpins the etiology ...
www.biorxiv.org
Read our latest @trendsbiochem review on mitochondrial compartmentalization #TiBS #mitochondria #alderlab
https://authors.elsevier.com/a/1dMjU3S6GfF7Vz#.YOWTPNyx9W0.twitter